UK Markets open in 1 hr 34 mins

Edwards Lifesciences Corporation (EW)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
109.49-3.16 (-2.81%)
At close: 04:00PM EST
109.79 +0.30 (+0.27%)
After hours: 07:18PM EST
Sign in to post a message.
  • A
    ANTHONY
    WouldJ&J buy EW? It would only make sense plus J&J has a market cap of over$ 400 billion . To me it would only make sense . They are also located I. The same are .
  • B
    Brendan
    This is not doing great
  • A
    Amar
    A bit concerning we haven't seen the early TAVR report yet. If it is a negative trial that is a real problem for the current valuation. Drop some at 127 and you will buy back at 110.
  • G
    GFA
    EW is a good stock to own with a great long-term story, but 42 times fwd. earnings is a steep multiple to pay, so any disappointment in growth trajectory or clinical trial results will lead to multiple compression.
  • A
    ANTHONY
    Nothing is doing great ! Thanks Joe .
  • A
    ANTHONY
    This would be a great buy today $107.00
  • Y
    Yahoo Finance Insights
    Edwards Lifesciences reached an all time high at 125.82
  • A
    ANTHONY
    A lot of movement today !
  • B
    Benrí
    EW is up 10% this month, 30% in 6 months and 53% in a year
  • n
    nick
    Is this the move some of us have been waiting for or are the markets still to choppy?
    Quick story: I bought in around $68 with more ammo available but never used any, just a couple weeks ago. It has floated around these prices for a bit and I was waiting for it to make a move. I missed the daily move upwards but this seems like big news for a company that is very well managed. I want to add more shares but I would also like to know the sentiment of the long positions. Is the China and settlement news as big as I hope?
  • A
    Amar
    I suspect the recent run up in the stock is due to the upcoming release of PARTNER III data for aortic valve replacement in low risk patients. This will increase the patient pool for aortic valve replacement by several fold and render conventional read - surgical AVR all but obsolete. which would you pick 4 week recovery or 4 day recovery. This is underappreciated by the retail investor but well known by the institutional investors. Good luck
  • S
    Scotty
    I work in the heart surgery business now for 26 years, involved with 4000 procedures , and I can tell you I bought $400,000 worth of this stock. Of course, hope I'm not wrong right? It takes a long time to get a valve to market, and the Edwards Sapien TAVR valve has superb market share and results. We did 15, then 50 and then 150 last year. Patients are learning about it , and that's what Mick Jagger got. I have great confidence in this stock, and also Medtronic, another holding. I bought in EW at 190, and again at 230. I don't think in 5 years I'll be doing Aortic Valve Replacements, just repairs or combination procedures if the heart is already going to be exposed. Also, the newer coatings on all valves are so much improved from the 80's and 90's one can expect a valve to last your lifetime. EW is also a really good company with lots of other product lines. I feel the same way as I did about Intuitive Surgical.
  • J
    JIII
    Proxy statement wants increase in shares to effect a 3:1 stock split. Is this a good idea? I know it should not make any difference, but not many companies are splitting their shares today. Any opinions appreciated.
  • g
    gary
    Latest heart valve just approved by China today. Huge market opened up.
  • S
    SV
    No major increase in the stock price in the last 6 months. Any possible reasons?
  • J
    JerelZ
    Stock usually drops after earning and starts to rise within a week - will be in the 170-180 range by the end of the year.
    One of the great medical innovative companies
  • C
    Chilln4Sure
    I've dedicated about 5% of my portfolio to EW for several years and wish I'd have increased that, no doubt, but the high P/E held me back. Help me out folks; Can this company protect its patent or proprietary advantage moving forward? It seems counterintuitive to pay triple my original price but this thing seems to only gain momentum and market share. Thanks.
  • A
    Amar
    Only 6 months to the release of the culmination of the TAVR trials EARLY TAVR which studies aortic valve replacement percutaneously in patients who have no symptoms i.e no fainting, chest pain or congestive heart failure. Looking at what happened with PARTNER I: 11$ - 16$ (Oct 2010), PARTNER II: 19 - 38 dollars (Apr 2016), and most recently PARTNER III (detailed below in the conversations). EARLY TAVR's release is the last chance investors may get to see a meteoric jump in EW. While growth and profits will continue - it would be wise not to miss this catalyst in December 2021. Good luck.
  • B
    Brian
    I follow heart related stocks and Edwards is a leader